RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | Clinical and Translational Medicine |
| Online Access: | https://doi.org/10.1002/ctm2.1098 |
| _version_ | 1797781014366388224 |
|---|---|
| author | Sidharth Jain Samantha Rego Steven Park Yiran Liu Simone Parn Kush Savsani David S. Perlin Sivanesan Dakshanamurthy |
| author_facet | Sidharth Jain Samantha Rego Steven Park Yiran Liu Simone Parn Kush Savsani David S. Perlin Sivanesan Dakshanamurthy |
| author_sort | Sidharth Jain |
| collection | DOAJ |
| first_indexed | 2024-03-12T23:51:48Z |
| format | Article |
| id | doaj.art-f6e9f19aee894a85827766a210d7f530 |
| institution | Directory Open Access Journal |
| issn | 2001-1326 |
| language | English |
| last_indexed | 2024-03-12T23:51:48Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Translational Medicine |
| spelling | doaj.art-f6e9f19aee894a85827766a210d7f5302023-07-13T14:36:42ZengWileyClinical and Translational Medicine2001-13262022-11-011211n/an/a10.1002/ctm2.1098RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviralSidharth Jain0Samantha Rego1Steven Park2Yiran Liu3Simone Parn4Kush Savsani5David S. Perlin6Sivanesan Dakshanamurthy7Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington DC District of Columbia 20057 USAGeorgetown College Georgetown University Washington DC District of Columbia 20057 USACenter for Discovery and Innovation Hackensack Meridian Health New Jersey 07110 USADepartment of Biochemistry & Molecular Biology Georgetown University Medical Center Washington DC District of Columbia 20057 USACollege of Arts & Science University of the District of Columbia Washington DC District of Columbia 20008 USACollege of Humanities and Sciences Virginia Commonwealth University Richmond Virginia 23284 USACenter for Discovery and Innovation Hackensack Meridian Health New Jersey 07110 USALombardi Comprehensive Cancer Center Georgetown University Medical Center Washington DC District of Columbia 20057 USAhttps://doi.org/10.1002/ctm2.1098 |
| spellingShingle | Sidharth Jain Samantha Rego Steven Park Yiran Liu Simone Parn Kush Savsani David S. Perlin Sivanesan Dakshanamurthy RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral Clinical and Translational Medicine |
| title | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_full | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_fullStr | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_full_unstemmed | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_short | RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral |
| title_sort | rnaseq profiling of covid19 infected patients identified an eif2ak2 inhibitor as a potent sars cov 2 antiviral |
| url | https://doi.org/10.1002/ctm2.1098 |
| work_keys_str_mv | AT sidharthjain rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT samantharego rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT stevenpark rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT yiranliu rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT simoneparn rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT kushsavsani rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT davidsperlin rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral AT sivanesandakshanamurthy rnaseqprofilingofcovid19infectedpatientsidentifiedaneif2ak2inhibitorasapotentsarscov2antiviral |